Incidence of infection associated with eculizumab: a meta-analysis of 9 randomized controlled trials.

Front Pharmacol · 2025 · PMC12067414 · PMID 40356951

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

In the 26–52 weeks subgroup, eculizumab appeared to exhibit a higher risk of general infection (RR = 1.22; 95% CI: 0.96–1.55; I 2 = 0%), though this difference did not reach statistical significance ( Supplementary Figure S3 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.